ICU seastarmedical.com: Multiplikator Forward P/S

SeaStar Medical develops systems to combat systemic inflammation, leveraging the expertise of bioengineers. However, business success depends on the outcome of clinical trials, where a lack of data creates financial threats. The forward P/S based on forecasts demonstrates the current valuation relative to expected revenue, and this metric stands at 2.10. The humanitarian status of the development for renal failure minimizes geopolitical risks.
Rincian metrik lan analitis perusahaan seastarmedical.com (ICU)

Use this tool for a comparative asset analysis, as it maps current market capitalization against projected annual sales volume. The trend of the forward P/S valuation reflects the justification of multiples through revenue expansion rates, which for SeaStar Medical (ICU) is confirmed by exclusive access to the dialysis market due to FDA protection that eliminates competition in the kidney treatment niche.